Pascal H.
- Country
- France
- Department
- Service oncologie digestive
Research Overview
- Phase 3 Study of Adjuvant Daraxonrasib Versus Observation in Patients With Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant or Adjuvant Chemotherapy
- Morning versus afternoon pembrolizumab administration with carboplatin-pemetrexed in stage IV non-squamous NSCLC: randomized phase III trial
- Phase 2/3 Randomized Study of Telisotuzumab Adizutecan Combined with FOLFOX versus Standard of Care in First‑Line Metastatic Pancreatic Ductal Adenocarcinoma
Data & Insights
Has run more than one trial at 128 of 328 partner sites.
Specializations
Pancreatic Cancer Research
This investigator demonstrates extensive involvement in pancreatic adenocarcinoma research, with particular focus on advanced and metastatic disease states. Their research encompasses various treatment approaches for locally advanced pancreatic cancer.
- Advanced Treatment Protocols
- Metastatic Disease Management
- Novel Therapeutic Combinations
Gastrointestinal Oncology
The investigator specializes in various gastrointestinal cancers, including colon carcinoma and gastric adenocarcinoma. Their work includes innovative approaches in hepatocellular carcinoma treatment.
- Digestive System Malignancies
- Advanced Therapeutic Strategies
- Immunotherapy Applications
Innovative Cancer Therapeutics
The investigator explores cutting-edge treatment approaches including circulating tumor DNA analysis and immunotherapy combinations. Their research includes studies on targeted molecular therapies.
- Biomarker-Driven Treatments
- Combination Therapy Strategies
- Maintenance Treatment Protocols
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.